Clinical Report: Menopause: New Target May Prevent Cognitive Decline
Overview
Research indicates that treatment with an estrogen receptor-β (ERβ) ligand can reverse hippocampal neuropathology in mid-aged mice. This study highlights the role of ERβ in astrocytes and its implications for cognitive function in aging.
Background
Cognitive decline during menopause is a significant concern for many women. This research focuses on the protective role of estrogen receptor-β in the brain, particularly in astrocytes.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
- Treatment with an ERβ ligand reversed hippocampal neuropathology in mid-aged mice.
- Cognitive deficits and hippocampal atrophy in aging female mice were linked to synaptic loss and increased glial activation due to ovarian hormone depletion.
- The study identified differentially expressed pathways in hippocampal astrocytes, including Gluconeogenesis I and Glycolysis I.
- Abnormal glucose metabolism gene expression found in mice was also observed in humans.
- Estriol, an estrogen that targets ERβ, has been used widely in Europe for 40 years.
- Previous clinical trials have not assessed cognitive improvement in menopausal women using estriol.
Clinical Implications
The study suggests that targeting estrogen receptor-β in astrocytes may have implications for cognitive function.
Conclusion
This study presents findings regarding the role of ERβ in cognitive health during menopause.
Related Resources & Content
- Dr. Rhonda R. Voskuhl, Conexiant, 2023 -- Menopause: New Target May Prevent Cognitive Decline
- conexiant — Menopause: More Cognitive Complaints, Not Decline
- conexiant — More Menopause Symptoms, Greater Cognitive Risk
- conexiant — Early Menopause Linked to Long-Term Cognitive Decline, Study
- conexiant — Menopause Treatment Shows No Brain Effects After Decade
- Menopause: More Cognitive Complaints, Not Decline
- More Menopause Symptoms, Greater Cognitive Risk
- Early Menopause Linked to Long-Term Cognitive Decline, Study
- Recommendations | Menopause: identification and management | Guidance | NICE
- NG23 Menopause evidence review G: dementia 07/11/2024
- FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
